Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tourian

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
CNS Spectrums|January 27, 2009
A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorderAlan D Feiger, Karen A Tourian, Gregory R Rosas, et al.
International Clinical Psychopharmacology|October 6, 2007
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorderLucia Septien-Velez, Bruno Pitrosky, Sudharshan Krishna Padmanabhan, et al.
Biological Psychiatry|June 8, 2007
A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorderJohn S March, A Richard Entusah, Moira Rynn, et al.
CNS Spectrums|May 2, 2009
An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorderAnita H Clayton, Susan G Kornstein, Gregory Rosas, et al.
Journal of Child and Adolescent Psychopharmacology|March 12, 2014
Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorderRobert L Findling, James Groark, Deborah Chiles, et al.
International Clinical Psychopharmacology|September 26, 2009
Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorderStuart A Montgomery, Maurizio Fava, Sudharshan K Padmanabhan, et al.
Current Medical Research and Opinion|May 30, 2008
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorderMichael R Liebowitz, Amy L Manley, Sudharshan K Padmanabhan, et al.
Pharmacopsychiatry|September 11, 2010
HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorderP Bech, P Boyer, J-M Germain, et al.
The Journal of Clinical Psychiatry|November 7, 2014
Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trialAnita H Clayton, Karen A Tourian, Kristen Focht, et al.
Journal of Child and Adolescent Psychopharmacology|July 19, 2016
Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive DisorderRobert L Findling, James Groark, Karen A Tourian, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
CNS Spectrums|January 27, 2009
A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorderAlan D Feiger, Karen A Tourian, Gregory R Rosas, et al.
International Clinical Psychopharmacology|October 6, 2007
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorderLucia Septien-Velez, Bruno Pitrosky, Sudharshan Krishna Padmanabhan, et al.
Biological Psychiatry|June 8, 2007
A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorderJohn S March, A Richard Entusah, Moira Rynn, et al.
CNS Spectrums|May 2, 2009
An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorderAnita H Clayton, Susan G Kornstein, Gregory Rosas, et al.
Journal of Child and Adolescent Psychopharmacology|March 12, 2014
Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorderRobert L Findling, James Groark, Deborah Chiles, et al.
International Clinical Psychopharmacology|September 26, 2009
Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorderStuart A Montgomery, Maurizio Fava, Sudharshan K Padmanabhan, et al.
Current Medical Research and Opinion|May 30, 2008
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorderMichael R Liebowitz, Amy L Manley, Sudharshan K Padmanabhan, et al.
Pharmacopsychiatry|September 11, 2010
HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorderP Bech, P Boyer, J-M Germain, et al.
The Journal of Clinical Psychiatry|November 7, 2014
Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trialAnita H Clayton, Karen A Tourian, Kristen Focht, et al.
Journal of Child and Adolescent Psychopharmacology|July 19, 2016
Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive DisorderRobert L Findling, James Groark, Karen A Tourian, et al.
Pageof 4